

CELGENE CORP /DE/
Form 8-K
December 10, 2007

ITEM 8.01 OTHER EVENTS

On December 9, 2007, Celgene International Sarl announced that updated clinical data from the Eastern Cooperative Oncology Group's, or ECOG, large, randomized Phase III trial evaluating oral REVLIMID® (lenalidomide) with low-dose dexamethasone continued to demonstrate superior overall survival rates for newly diagnosed multiple myeloma patients compared to REVLIMID® with the standard high-dose dexamethasone. Overall survival, the most important outcome for patients and physicians, is 96% at one year and 87% at two years. The efficacy data (Abstract #74), presented at the 49th annual meeting of the American Society of Hematology, or ASH, for the first time expand on initial safety analysis presented in June.

Attached hereto and incorporated herein by reference as Exhibit 99.1 is the Press Release announcing such information.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibit 99.1 – Press Release dated December 9, 2007

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CELGENE CORPORATION

Date: December 10, 2007

By: /s/ David W. Gyska

Name: David W. Gyska
Title: Sr. Vice President and Chief Financial
Officer